Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
Efficacy and Safety of 186 Mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents with Chronic Rhinosinusitis Without Nasal Polyps
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT06850805
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
- Conditions
- Eosinophilic Esophagitis
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT06705387
- Locations
- 🇺🇸
Children's Hospital Colorado/University of Colorado School of Medicine, Aurora, Colorado, United States
CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Università degli Studi di Ferrara
- Target Recruit Count
- 80
- Registration Number
- NCT06482294
- Locations
- 🇮🇹
Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
- Conditions
- Asthma
- Interventions
- Drug: Inhaled corticosteroids/long-acting beta-2 agonists
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1358
- Registration Number
- NCT06372496
- Locations
- 🇨🇳
GSK Investigational Site, Taichung, Taiwan
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Comparator - Trimbow®
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 1252
- Registration Number
- NCT06234345
- Locations
- 🇧🇷
Eurofarma Laboratorios S.A, São Paulo, Padrão, Brazil
Advair HFA in Healthy and HAPE Predisposed Subjects
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 60
- Registration Number
- NCT06040268
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06025214
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05982990
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
- Conditions
- Lung DiseasesBronchiolitis ObliteransChronic Graft Versus Host DiseaseBronchiolitis Obliterans Syndrome
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05922761
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Susanna Naggie, MD
- Target Recruit Count
- 1407
- Registration Number
- NCT05736874
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.